Optimizing Outcomes in Myasthenia Gravis: Therapeutic Advances and Value-Based Care Models

Program Description

Myasthenia gravis (MG) is an autoimmune condition characterized by muscle weakness and fatigue, which can affect patients' quality of life. MG typically presents as ocular weakness, with 90% of MG crises or exacerbations occurring within 2 years of initial presentation. Standard treatment approaches incorporate immunosuppressive therapies, including long-term steroid use, but these can lead to treatment complications, and patients may not achieve optimal outcomes with these conventional approaches. New biologics targeting complement, FcRn, and B cells have shown sustained, long-term effects and good safety and tolerability in MG, yet many patients still face access barriers due to high treatment costs that can hinder their effective use. Managed care pharmacists play a crucial role in addressing these challenges by developing evidence-based guidance that supports care tailored to individual patient needs. This webinar will explore how emerging therapies in MG can be incorporated into personalized disease management approaches to minimize the impact of MG exacerbations and hospitalization. Key discussion points such as dosing schedules, disease control, and patient-reported outcomes will inform managed care decision-making regarding health care resource utilization, medical and pharmacy cost considerations, and the integration of emerging agents into the current treatment landscape for MG.

Target audience: Managed Care Pharmacist
Type of activity: Application
Release date: August 29, 2025
Expiration date: August 31, 2026
Time to complete activity: 1.0 hour
Learner level: Foundational, Intermediate
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

1. Examine the pathophysiology and classification of myasthenia gravis (MG) and its impact on patient health and quality of life.

2. Assess the efficacy and safety profiles of novel and emerging targeted therapies for the management of MG.

3. Analyze the economic challenges associated with MG and discuss value-based approaches to improve timely and appropriate access to innovative treatments.

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hours (0.10 CEU) under the ACPE universal activity number 0290-0000-25-291-H01-P. The activity is available for CE credit through August 31, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Amy M. Lugo, PharmD, BCPS, BC-ADM, FAPhA

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Rose Buszka, PharmD, BCPS, CHCP; Crissy Wilson; Susan Pordon; Brianna Winters; and Chloe Taccetta have no relevant financial relationships with commercial interests to disclose.
At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
ceinfo@pharmacytimes.com
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms